{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T14:31:22Z","timestamp":1763389882733,"version":"3.37.3"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019721","name":"Roche Farma SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.msard.2024.105732","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T16:27:29Z","timestamp":1718641649000},"page":"105732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Preferences for neuromyelitis optica spectrum disorder treatments: A conjoint analysis with neurologists in Spain"],"prefix":"10.1016","volume":"88","author":[{"given":"Nieves","family":"T\u00e9llez-Lara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9582-9230","authenticated-orcid":false,"given":"Roc\u00edo","family":"G\u00f3mez-Ballesteros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Sep\u00falveda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida","family":"Orviz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"D\u00edaz-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabas","family":"Boyero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Aguado-Valcarcel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Cobo-Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paloma","family":"L\u00f3pez-Laiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Rebollo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Maurino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.msard.2024.105732_bib0001","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3390\/jpm12020274","article-title":"Conjoint Analysis: a Research Method to Study Patients' Preferences and Personalize Care","volume":"12","author":"Al-Omari","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.msard.2024.105732_bib0002","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.msard.2018.12.010","article-title":"Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment","volume":"28","author":"Banerjee","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105732_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1099376","article-title":"A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder","volume":"14","author":"Berthele","year":"2023","journal-title":"Front. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2024.105732_bib0004","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00415-015-8005-z","article-title":"Multiple sclerosis in men: management considerations","volume":"263","author":"Bove","year":"2016","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2024.105732_bib0005","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s40120-022-00349-5","article-title":"A Targeted Literature Search and Phenomenological Review of Perspectives of People with Multiple Sclerosis and Healthcare Professionals of the Immunology of Disease-Modifying Therapies","volume":"11","author":"Burtchell","year":"2022","journal-title":"Neurol. Ther."},{"issue":"1","key":"10.1016\/j.msard.2024.105732_bib0006","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J. Neuroinflammation."},{"issue":"4","key":"10.1016\/j.msard.2024.105732_bib0007","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2165\/00148365-200605040-00006","article-title":"Maximising responses to discrete choice experiments: a randomised trial","volume":"5","author":"Coast","year":"2006","journal-title":"Appl. Health. Econ. Health. Policy."},{"issue":"3","key":"10.1016\/j.msard.2024.105732_bib0008","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/MLR.0b013e318280f02c","article-title":"Validation of a 10-item care-related regret intensity scale (RIS-10) for health care professionals","volume":"51","author":"Courvoisier","year":"2013","journal-title":"Med. Care."},{"issue":"10206","key":"10.1016\/j.msard.2024.105732_bib0009","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.msard.2024.105732_bib0010","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/JNN.0000000000000661","article-title":"Preferences Toward Attributes of Disease-Modifying Therapies: the Role of Nurses in Multiple Sclerosis Care","volume":"54","author":"Del R\u00edo-Mu\u00f1oz","year":"2022","journal-title":"J. Neurosci. Nurs."},{"issue":"1","key":"10.1016\/j.msard.2024.105732_bib0011","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/0272989X9901900105","article-title":"A method for evaluating health care providers' decision making: the provider decision process assessment instrument","volume":"19","author":"Dolan","year":"1999","journal-title":"Med. Decis. Making."},{"key":"10.1016\/j.msard.2024.105732_bib0012","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.msard.2017.07.014","article-title":"Patient perspectives on neuromyelitis optica spectrum disorders: data from the PatientsLikeMe online community","volume":"17","author":"Eaneff","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2024.105732_bib0013","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1007\/s00415-022-11529-6","article-title":"Clinical and epidemiological correlates of treatment change in patients with NMOSD: insights from the CIRCLES cohort","volume":"270","author":"Gholizadeh","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.105732_bib0014","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2147\/PPA.S53140","article-title":"Treatment selection and experience in multiple sclerosis: survey of neurologists","volume":"8","author":"Hanson","year":"2014","journal-title":"Patient. Prefer. Adherence."},{"key":"10.1016\/j.msard.2024.105732_bib0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/ITT.S287652","article-title":"Drug Treatment of Neuromyelitis Optica Spectrum Disorders: out with the Old, in with the New?","volume":"10","author":"Held","year":"2021","journal-title":"Immunotargets. Ther."},{"issue":"5","key":"10.1016\/j.msard.2024.105732_bib0016","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s10459-018-9839-9","article-title":"The Jefferson Scale of Empathy: a nationwide study of measurement properties, underlying components, latent variable structure, and national norms in medical students","volume":"23","author":"Hojat","year":"2018","journal-title":"Adv. Health. Sci. Educ. Theory. Pract."},{"issue":"1","key":"10.1016\/j.msard.2024.105732_bib0017","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1037\/a0017820","article-title":"Gender-role attitudes and behavior across the transition to parenthood","volume":"46","author":"Katz-Wise","year":"2010","journal-title":"Dev. Psychol."},{"key":"10.1016\/j.msard.2024.105732_bib0018","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3389\/fneur.2020.00537","article-title":"Relapse Patterns in NMOSD: evidence for earlier occurrence of optic neuritis and possible seasonal variation","volume":"11","author":"Khalilidehkordi","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2024.105732_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103500","article-title":"Quality of life of patients with multiple sclerosis and neuromyelitis optica spectrum disorders: cross-sectional and longitudinal analysis","volume":"58","author":"Kim","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2024.105732_bib0020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40120-021-00311-x","article-title":"Evaluating the economic burden of relapses in neuromyelitis optica spectrum disorder: a real-world analysis using german claims data","volume":"11","author":"Knapp","year":"2022","journal-title":"Neurol. Ther."},{"issue":"1","key":"10.1016\/j.msard.2024.105732_bib0021","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/hex.12599","article-title":"Comparison of preferences of healthcare professionals and MS patients for attributes of disease-modifying drugs: a best-worst scaling","volume":"21","author":"Kremer","year":"2018","journal-title":"Health. Expect."},{"key":"10.1016\/j.msard.2024.105732_bib0022","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2147\/PPA.S306498","article-title":"Patient and neurologist preferences in the united states for relapsing-remitting multiple sclerosis treatments: findings from a discrete choice experiment","volume":"15","author":"Kumar","year":"2021","journal-title":"Patient. Prefer. Adherence."},{"issue":"2","key":"10.1016\/j.msard.2024.105732_bib0023","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3988\/jcn.2022.18.2.207","article-title":"Results of a survey on diagnostic procedures and treatment choices for neuromyelitis optica spectrum disorder in korea: beyond the context of current clinical guidelines","volume":"18","author":"Lee","year":"2022","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.msard.2024.105732_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102522","article-title":"Risk of relapse in patients with neuromyelitis optica spectrum disorder: recognition and preventive strategy","volume":"46","author":"Ma","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2024.105732_bib0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/pharmacy8020061","article-title":"Assessing pharmacists' preferences towards efficacy attributes of disease-modifying therapies in relapsing-remitting multiple sclerosis","volume":"8","author":"Mart\u00ednez-L\u00f3pez","year":"2020","journal-title":"Pharmacy. (Basel)"},{"issue":"3","key":"10.1016\/j.msard.2024.105732_bib0026","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s40120-022-00356-6","article-title":"Impact of neuromyelitis optica spectrum disorder on quality of life from the patients' perspective: an observational cross-sectional study","volume":"11","author":"Meca-Lallana","year":"2022","journal-title":"Neurol. Ther."},{"issue":"2","key":"10.1016\/j.msard.2024.105732_bib0027","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s40120-022-00431-y","article-title":"Understanding treatment decisions in neuromyelitis optica spectrum disorder: a global clinical record review with patient interviews","volume":"12","author":"Min","year":"2023","journal-title":"Neurol. Ther."},{"issue":"2","key":"10.1016\/j.msard.2024.105732_bib0028","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of neuromyelitis optica: a systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology."},{"issue":"4","key":"10.1016\/j.msard.2024.105732_bib0029","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200124","article-title":"International delphi consensus on the management of AQP4-IgG+ NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab","volume":"10","author":"Paul","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"7","key":"10.1016\/j.msard.2024.105732_bib0030","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2024.105732_bib0031","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2024.105732_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103083","article-title":"Status of the neuromyelitis optica spectrum disorder in Latin America","volume":"53","author":"Rivera","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2024.105732_bib0033","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12874-020-01126-4","article-title":"Confirmatory factor analysis of the Evidence-Based Practice Attitude Scale (EBPAS) in a large and representative Swedish sample: is the use of the total scale and subscale scores justified?","volume":"20","author":"Santesson","year":"2020","journal-title":"BMC,Med, Res, Methodol"},{"issue":"1","key":"10.1016\/j.msard.2024.105732_bib0034","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12911-016-0377-1","article-title":"Cognitive biases associated with medical decisions: a systematic review","volume":"16","author":"Saposnik","year":"2016","journal-title":"BMC. Med. Inform. Decis. Mak."},{"issue":"1","key":"10.1016\/j.msard.2024.105732_bib0035","article-title":"Does attendance at the ECTRIMS congress impact on therapeutic decisions in multiple sclerosis care?","volume":"5","author":"Saposnik","year":"2019","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"12","key":"10.1016\/j.msard.2024.105732_bib0036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261050","article-title":"Behavioral aspects of nurse practitioners associated with optimal multiple sclerosis care in Spain","volume":"16","author":"Saposnik","year":"2021","journal-title":"PLoS. One."},{"issue":"14","key":"10.1016\/j.msard.2024.105732_bib0037","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1177\/1352458517735191","article-title":"Epidemiology of NMOSD in Catalonia: influence of the new 2015 criteria in incidence and prevalence estimates","volume":"24","author":"Sep\u00falveda","year":"2018","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2024.105732_bib0038","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.msard.2024.105732_bib0039","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11940-021-00667-3","article-title":"New therapeutic landscape in neuromyelitis optica","volume":"23","author":"Tugizova","year":"2021","journal-title":"Curr. Treat. Options. Neurol."},{"key":"10.1016\/j.msard.2024.105732_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102869","article-title":"Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature","volume":"50","author":"Velasco","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2024.105732_bib0041","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40271-017-0296-y","article-title":"A systematic review of discrete-choice experiments and conjoint analysis studies in people with multiple sclerosis","volume":"11","author":"Webb","year":"2018","journal-title":"Patient."},{"issue":"7","key":"10.1016\/j.msard.2024.105732_bib0042","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"12\u2013a","key":"10.1016\/j.msard.2024.105732_bib0043","first-page":"S3","article-title":"Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder","volume":"28","author":"Wingerchuk","year":"2022","journal-title":"J. Manag. Care. Spec. Pharm."},{"issue":"1","key":"10.1016\/j.msard.2024.105732_bib0044","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40120-021-00295-8","article-title":"Network meta-analysis of food and drug administration-approved treatment options for adults with aquaporin-4 immunoglobulin g-positive neuromyelitis optica spectrum disorder","volume":"11","author":"Wingerchuk","year":"2022","journal-title":"Neurol. Ther."},{"issue":"10","key":"10.1016\/j.msard.2024.105732_bib0045","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1007\/s11606-020-06467-w","article-title":"Impact of physicians' personalities and behavioral traits on treatment-related decision-making for elderly acute myeloid leukemia","volume":"36","author":"Wu","year":"2021","journal-title":"J. Gen. Intern. Med."},{"issue":"22","key":"10.1016\/j.msard.2024.105732_bib0046","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2024.105732_bib0047","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/bdm.2102","article-title":"Development and validation of the general risk propensity scale (GRiPS)","volume":"32","author":"Zhang","year":"2018","journal-title":"Behav. Decis. Mak."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824003092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824003092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T01:03:20Z","timestamp":1732237400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824003092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":47,"alternative-id":["S2211034824003092"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105732","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preferences for neuromyelitis optica spectrum disorder treatments: A conjoint analysis with neurologists in Spain","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105732","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105732"}}